Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06366698 · ClinicalTrials.gov registry record · Phase 3
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
A Phase 3 study of Iron Deficiency Anemia of Pregnancy, sponsored by Arrowhead Regional Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 1
- Study location
NCT06366698: Recruiting Phase 3 study of Iron Deficiency Anemia of Pregnancy, sponsored by Arrowhead Regional Medical Center.
NCT06366698 is a Phase 3 study of Iron Deficiency Anemia of Pregnancy that is actively recruiting participants, run by Arrowhead Regional Medical Center. The registered enrollment target is 900 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06366698, a Phase 3 study of Iron Deficiency Anemia of Pregnancy, is actively recruiting participants, sponsored by Arrowhead Regional Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.
Conditions Studied
Interventions
- DRUG Venofer 200 MG Per 10 ML Injection
- DRUG Ferrous sulfate
Study Locations (1)
California
- Arrowhead Regional Medical Center - Colton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 3 |
What NCT06366698 shows while recruiting
NCT06366698 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Iron Deficiency Anemia of Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which Venofer 200 MG Per 10 ML Injection is the first listed.
NCT06366698 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06366698 about?
NCT06366698 is a clinical study titled "Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia". This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency ane...
What is the current status of trial NCT06366698?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2023-11-21. Estimated completion is 2025-12-30.
What conditions does trial NCT06366698 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia of Pregnancy.
What interventions are being tested in trial NCT06366698?
The interventions under investigation include: Venofer 200 MG Per 10 ML Injection (DRUG), Ferrous sulfate (DRUG).
Who is sponsoring clinical trial NCT06366698?
This trial is sponsored by Arrowhead Regional Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06366698 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia of Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06366698's enrollment target sits among peer trials
900 350th of 2000 higher than 1,642 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI